Images List Premium Download Classic

Isoquinolin

Isoquinolin-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Polymerizable liquid crystal compound, composition, liquid crystal polymerization film-kind thereof and use thereof
June 22, 2017 - N°20170174992

In which, in formula (1), g is a group composed of a quinoline skeleton, an isoquinoline skeleton, a quinoxaline skeleton or a quinazoline skeleton, a1 is 1,4-phenylene or 1,4-cyclohexylene, z1 is a connecting group, m is an integer from 0 to 3, and r1 is a group containing a polymerizable group.
Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine
June 22, 2017 - N°20170174637

Or a salt thereof, and a polymorph of compound a dihydrochloride salt:
Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
Arqule, Inc.
June 22, 2017 - N°20170174636

The present application provides solid forms of (r)-6-(2-fluorophenyl)-n-(3-(2-(2-methoxyethylamino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine dihydrochloride, and methods of preparing and using same.
Isoquinolin Patent Pack
Download + patent application PDFs
Isoquinolin Patent Applications
Download + Isoquinolin-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Isoquinolin-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Method for a pesticide having an insecticide, acaricide and nematicide action based on isoquinoline alkaloids ...
Promotora Tecnica Industrial, S.a. De C.v.
June 08, 2017 - N°20170156345

The method for a pesticide having an insecticide, acaricide and nematicide action is obtained from plant extracts that have important synergic interactions in pesticide activity. The characteristics of the pesticide are efficient control of insects, mites and nematodes, low toxicity for mammals and low persistence in the environment. This pesticide is a composition based on plant extracts containing isoquinoline alkaloids ...
Tetrahydroisoquinolinone derivatives and their use in the inhibition of the hsp70 protein
Julius-maximilians-universitaet Wuerzburg
June 01, 2017 - N°20170152229

The present invention relates to tetrahydroisoquinolinone derivatives, a pharmaceutical composition comprising the same and the use of these derivatives in the inhibition of the hsp70 protein. The compounds are useful in the treatment or inhibition of cancer, autoimmune disease, rheumatoid arthritis, inflammatory bowel disease and psoriasis.
Benzylisoquinoline alkaloids (bia) producing microbes, and methods of making and using the same
Julius-maximilians-universitaet Wuerzburg
May 25, 2017 - N°20170145454

Aspects of the invention include host cells that are engineered to produce benzylisoquinoline alkaloids (bias). The host cells include heterologous coding sequences for a variety of enzymes involved in synthetic pathways from starting compounds to bias of the host cell. Also provided are methods of producing the bias of interest by culturing the host cells under culture conditions that promote ...
Isoquinolin Patent Pack
Download + patent application PDFs
Isoquinolin Patent Applications
Download + Isoquinolin-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Isoquinolin-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Valbenazine salts and polymorphs thereof
Julius-maximilians-universitaet Wuerzburg
May 25, 2017 - N°20170145008

Provided herein are salts of (s)-2-amino-3-methyl-butyric acid (2r,3r,11br)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-yl ester in amorphous and crystalline forms, and processes of preparation, and pharmaceutical compositions thereof. Also provided are methods of their use for treating, preventing, or ameliorating one or more symptoms of neurological disorders and diseases including hyperkinetic movement disorders ...
Pharmaceutical combinations
Julius-maximilians-universitaet Wuerzburg
May 25, 2017 - N°20170143723

The disclosure relates to a pharmaceutical combination of a mdm2/4 inhibitor, namely (s)-1-(4-chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2h-isoquinolin-3-one or (s)-5-(5-chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1h-pyrrolo[3,4-d]imidazol-4-one, and a cyclin dependent ...
Isoquinoline compounds, a process for their preparation, and pharmaceutical compositions containing them
Julius-maximilians-universitaet Wuerzburg
May 18, 2017 - N°20170137385

Medicinal products containing the same which are useful in treating or preventing pathologies which are the result of activation of the rhoa/rock pathway and phosphorylation of the myosin light chain.
Process and intermediates for the synthesis of (r)-praziquantel
Tongli Biomedical Co., Ltd.
May 04, 2017 - N°20170121330

The present disclosure relates to a process and new intermediates for the synthesis of (r)-praziquantel, which is obtained through four steps in proper order, that is, condensation reaction, reduction reaction, acylation reaction and ring-closing reaction, using (1r)-2-substituted-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid as starting material. Overall, the present disclosure provides a (r)-praziquantel product with higher optical purity through ...
New treatment
Verona Pharma Plc
April 27, 2017 - N°20170112839

The invention provides a compound for use in treating or preventing a disease or condition selected from cystic fibrosis, chronic obstructive pulmonary disease (copd), asthma, mild pulmonary disease, bronchitis, bronchiectasis, idiopathic bronchiectasis, allergic bronchopulmonary aspergillosis, sinusitis, rhinosinusitis, cftr-related metabolic syndrome (crms), pancreatitis, idiopathic chronic pancreatitis and sjörgren's syndrome, or for use in preventing male infertility caused by congenital ...
8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives
Actelion Pharmaceuticals Ltd
April 20, 2017 - N°20170107214

The invention relates to compounds of formula (i) wherein r1, r2, r3, r4 and r5 are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as modulators of the cxcr3 receptor.
Process for the preparation of (s)-2-((4r,4as,6r,7r,7ar,12bs)-7,9...
Noramco, Inc.
April 13, 2017 - N°20170101415

An invention includes a process for the preparation of (s)-2((4r,4as,6r,7r,7ar,12bs)-7,9-dimethoxy-1,2,3,4,5,6,7,7a-octahydro-4a,7-ethano-4,12-methanobenzofuro[3,2-e]isoquinolin-6-yl)-3,3-dimethylbutan-2-ol.
Isoquinolin Patent Pack
Download + patent application PDFs
Isoquinolin Patent Applications
Download + Isoquinolin-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Isoquinolin-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Encapsulation of isoquinoline alkaloids
Rhizofeed, Llc
April 06, 2017 - N°20170095467

Processes of extracting isoquinoline alkaloids from natural sources and encapsulating the alkaloids in an alginate and inulin matrix are provided. The isoquinoline alkaloid encapsulates are useful as animal feed.
Selective androgen receptor degrader (sard) ligands and methods of use thereof
University Of Tennessee Research Foundation
April 06, 2017 - N°20170095446

This invention provides novel indole, indazole, benzimidazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (sard) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia or other hyper androgenic dermal diseases, kennedy's disease, amyotrophic lateral sclerosis (als), and uterine fibroids, and to methods for reducing the levels of androgen ...
Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the ...
Infinity Pharmaceuticals, Inc.
March 30, 2017 - N°20170088553

Solid forms of chemical compounds that modulate kinase activity, including pi3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including pi3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphic forms, cocrystals, and amorphous forms thereof, and pharmaceutical compositions thereof.
Electron transport layer and film having improved thermal stability
Rohm And Haas Electronic Materials Llc
March 23, 2017 - N°20170084847

Aspects of the invention provide a composition having a blend of an electron transport material and an organo alkali-metal salt wherein the salt has a glass transition greater than 115° c. The organo-alkali metal salt may be selected from the group consisting of lithium 2-(2-pyridyl)phenolate (lipp), lithium 2-(2′,2″-bipyridine-6′-yl)phenolate (libpp), 2-(isoquinoline-10-yl)...
Crystalline form of 6-[(4r)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile
Pfizer Inc.
March 16, 2017 - N°20170073338

This invention relates to a novel crystalline form of 6-[(4r)-4-methyl-1,1-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile which is useful as a selective androgen receptor modulator (sarm), and to compositions thereof and suitable processes for the preparation thereof.
Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
Pfizer Inc.
March 16, 2017 - N°20170073330

Or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor xia and/or plasma kallikrein which may be used as medicaments.
Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Aerie Pharmaceuticals, Inc.
March 16, 2017 - N°20170073325

Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as ...
Treatment of hyperkinetic movement disorders
Neurocrine Biosciences, Inc.
March 16, 2017 - N°20170071932

Methods for treating hyperkinetic diseases and disorders, such as tardive dyskinesia, are provided. In a certain embodiment, the potent vmat2 inhibitor (+)α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol ((+)α-htbz) is used in the methods described herein for treating a subject in need thereof.
Loading